From nanotechnology to immunomodulation: emerging strategies targeting macrophages in high altitude pulmonary hypertension
Abstract
High altitude pulmonary hypertension (HAPH) is a public health issue in high-altitude regions, characterized by increased pulmonary artery pressure, pulmonary vascular remodeling, and right heart failure, leading to the high incidence rate and high mortality. Current therapies can alleviate patient symptoms but provide limited control over disease progression. Immune regulation has gained recognition as a central driver of HAPH. Among immune cells, macrophages, as key immune regulators in the lung, orchestrate HAPH pathogenesis through recruitment, M1/M2 polarization, inflammatory activation, metabolic reprogramming, and crosstalk with pulmonary vascular cells. Targeting macrophages has emerged as a promising therapeutic strategy. Nanoplatforms provide powerful tools to enable precise targeting and functional modulation of macrophages in HAPH, as nanoplatforms such as liposomes, polymeric nanoparticles, and exosomes enable targeted delivery and controlled release, thereby facilitating precise regulation of the pulmonary immune microenvironment, including both macrophages and pulmonary vascular cells. Recent advances in nanoplatforms have enabled the development of macrophage focused precision interventions. In this review, we first outline the pathogenic roles of macrophages in the development and progression of HAPH. We then summarize the therapeutic potential of nanoplatform-based approaches in HAPH, with a particular focus on emerging nanomaterial-based strategies that…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.